Temocapril
Based on 2 publication(s) in Google Scholar
Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.14%
- CAS. Nr.: 111902-57-9
- Formel: C23H28N2O5S2
- Molecular Weight:476.61
-
Speicherung:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Angiogenesis-Related Compound Library
HY-L088
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Temocapril
More
Biologische Aktivität
Angiotensin-converting Enzyme (ACE)[1]
Temocapril hydrochloride is a prodrug of the ACE inhibitor, Temocaprilat. Temocapril hydrochloride can be readily uptaken via the small intestine, and then be converted to its active metabolite (temocaprilat) by CES1 (human carboxylesterase 1) in the liver[1].
Temocapril hydrochloride (500 nM) reduces the inhibitory effects of RS (N-acetyltetradecapeptide renin substrate) and AngI (angiotensin) on neurogenic vasodilation in the spontaneously hypertensive rats (SHR)[2].
Temocapril hydrochloride (0.1-10 μM; 24 h) shows inductive effects on redox proteins thioredoxin (TRX) while no effect on antioxidant enzymes Cu/ZnSOD and Mn-SOD expressions[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Cultured neonatal rat cardiomyocytes
-
Concentration:0.1 μM, 1 μM, 10 μM
-
Incubation Time:24 hours
-
Result:Enhanced redox proteins thioredoxin (TRX) expression 1.9-fold at 10 μM without affecting TRX2, Cu/Zn-SOD or Mn-SOD protein expression.
Temocapril (30 mg/kg; p.o.; daily; for 4 weeks) suppresses Angiotensin I-induced hypertension, plasma and renal ACE activity, but fails to reduce the level of Ang II in the kidney[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Experimental autoimmune myocarditis (EAM) rat model[3]
-
Dosage:10 mg/kg
-
Administration:Oral gavage; administration by water; 21 days
-
Result:Ameliorated EAM and prevented cellular proteins from oxidation.
Enhanced cardiomyocyte redox regulatory protein TRX expression.
-
Animal Model:Male Sprague Dawley rats[4]
-
Dosage:30 mg/kg
-
Administration:Oral gavage, daily, for 4 weeks
-
Result:Suppressed the blood pressure elevation induced by Ang I.
Chemical Information
-
CAS. Nr. 111902-57-9
-
Appearance Solid
-
Molecular Weight 476.61
-
Formel C23H28N2O5S2
-
Color Off-white to yellow
-
SMILES
O=C(O)CN1C[C@@H](C2=CC=CS2)SC[C@H](N[C@H](C(OCC)=O)CCC3=CC=CC=C3)C1=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (209.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Fukami T, et al. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos. 2010 Dec;38(12):2173-8. [Content Brief]
[2]. Kawasaki H, et al. Angiotensin inhibits neurotransmission of calcitonin gene-related peptide-containing vasodilator nerves in mesenteric artery of spontaneously hypertensive rats. J Pharmacol Exp Ther. 1998 Feb;284(2):508-15. [Content Brief]
[3]. Yuan Z, et al. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Cardiovasc Res. 2002 Aug 1;55(2):320-8. [Content Brief]
[4]. Ohnishi K, et al. Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats. J Pharmacol Sci. 2013;122(2):103-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0982 mL | 10.4908 mL | 20.9815 mL | 52.4538 mL |
| 5 mM | 0.4196 mL | 2.0982 mL | 4.1963 mL | 10.4908 mL | |
| 10 mM | 0.2098 mL | 1.0491 mL | 2.0982 mL | 5.2454 mL | |
| 15 mM | 0.1399 mL | 0.6994 mL | 1.3988 mL | 3.4969 mL | |
| 20 mM | 0.1049 mL | 0.5245 mL | 1.0491 mL | 2.6227 mL | |
| 25 mM | 0.0839 mL | 0.4196 mL | 0.8393 mL | 2.0982 mL | |
| 30 mM | 0.0699 mL | 0.3497 mL | 0.6994 mL | 1.7485 mL | |
| 40 mM | 0.0525 mL | 0.2623 mL | 0.5245 mL | 1.3113 mL | |
| 50 mM | 0.0420 mL | 0.2098 mL | 0.4196 mL | 1.0491 mL | |
| 60 mM | 0.0350 mL | 0.1748 mL | 0.3497 mL | 0.8742 mL | |
| 80 mM | 0.0262 mL | 0.1311 mL | 0.2623 mL | 0.6557 mL | |
| 100 mM | 0.0210 mL | 0.1049 mL | 0.2098 mL | 0.5245 mL |
Temocapril Related Classifications
HY-100713 Related Classifications
Powered by Bioz
- Temocapril
- 111902-57-9
- Angiotensin-converting Enzyme (ACE)
- Temocaprilat
- angiotensin-converting
- enzyme
- Angiotensin (I)
- hypertension
- heart failure
- acute myocardial infarction
- insulin resistance
- renal diseases
- redox proteins TRX
- CES1
- human carboxylesterase
- neonatal rat cardiomyocytes
- N-acetyltetradecapeptide renin substrate
- Cu/ZnSOD
- Mn-SOD
- Inhibitor
- inhibitor
- inhibit